BackEuropean Biotech Acquisition - Units (1 Ord Share Class A & 1/3 War) Overview

European Biotech Acquisition - Units (1 Ord Share Class A & 1/3 War) Total Assets

Latest total assets for EBACU: $130M.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$129.75M
↑ 1.00% YoYΔ $1.28M vs prior year quarter

Peer trimmed avg / median

Loading

European Biotech Acquisition - Units (1 Ord Share Class A & 1/3 War) Total Assets History

Loading

European Biotech Acquisition - Units (1 Ord Share Class A & 1/3 War) vs. peers: Total Assets Comparison

Loading

European Biotech Acquisition - Units (1 Ord Share Class A & 1/3 War) Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

European Biotech Acquisition - Units (1 Ord Share Class A & 1/3 War) (EBACU) FAQ

The latest total assets for EBACU is $130M as of December 2022. That compares with $130M in the prior-year period — up 1.0% year over year. Investors often review this figure alongside European Biotech Acquisition - Units (1 Ord Share Class A & 1/3 War)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, EBACU's total assets moved from $130M to $130M — a 1.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in European Biotech Acquisition - Units (1 Ord Share Class A & 1/3 War)'s operating scale or balance-sheet position.

A total assets figure of $130M for EBACU is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting EBACU's total assets ($130M), review year-over-year change from $130M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.